Navigation Links
ASTRO chairman to testify at CARE Act hearing
Date:6/8/2012

American Society for Radiation Oncology (ASTRO) Chairman Leonard Gunderson, MD, MS, FASTRO, will testify before the House Committee on Energy and Commerce Subcommittee on Health today on provisions of the Consistency, Accuracy, Responsibility, and Excellence in Medical Imaging and Radiation Therapy Act of 2011 (CARE Act) related to training and credentialing for medical imaging and radiation therapy technologists.

ASTRO strongly supports immediate passage of the CARE Act, which sets needed education and certification standards for radiation therapists, medical physicists and medical dosimetristscritical members of the team that delivers radiation therapy to cancer patients. Setting these minimum standards will help to ensure patients are treated accurately and safely and lead to fewer complications.

Today's hearing, "Examining the Appropriateness of Standards for Medical Imaging and Radiation Therapy Technologists," will examine the current state of training, identify any areas of deficiency and suggest ways of ensuring personnel have the appropriate background in the technical components of delivering treatments.

ASTRO has a long history of advocating to Congress on the need for improved safety in radiation therapy and creating minimum education and credentialing standards for treatment team members. This is also a core component of Target Safely, ASTRO's patient protection initiative, which was established in 2009 to ensure patients are receiving the safest treatments for their cancer.

Dr. Gunderson's testimony will inform Congress and the public that radiation therapy has been used for over 100 years as a safe and effective treatment for cancer with minimal side effects and that ASTRO is a leader in ensuring this continues. The testimony will outline several safety and patient quality initiatives the Society is working on to improve the quality of patient treatment and care, including:

  • Building on the bipartisan Patient Safety Act of 2005 by beginning work with a certified Patient Safety Organization to create the first national medical error reporting system for radiation oncology.
  • Assisting the Radiation Oncology Institute, ASTRO's foundation, in developing the National Radiation Oncology Registry, which will improve cancer patients' care by capturing real-time information on radiation treatment delivery and health outcomes.
  • Supporting physician participation in maintenance of certification activities and other continuing medical education programs to ensure all physicians are up-to-date on the latest treatment approaches.

These initiatives together with the CARE Act can prevent medical errors that can occur in a complex treatment such as radiation therapy.

Dr. Gunderson will testify that ASTRO wants patients to have peace of mind when it comes to safety, quality and efficacy of radiation therapy, and the CARE Act is a critical step toward that goal. ASTRO looks forward to working with Congress on additional policies that could be implemented to further enhance the quality of care patients receive.


'/>"/>

Contact: Nicole Napoli
nicolen@astro.org
703-839-7336
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
2. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
3. Gastro Woes Often Strike Rheumatoid Arthritis Patients
4. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
5. Football-related catastrophic brain injuries on the rise
6. Catastrophic Head Injuries to High School Football Players Rising
7. Gastroenterology special issue focuses on new directions of viral hepatitis care and research
8. Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy
9. ASTRO wins 2012 Communicator Award
10. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
11. Cone beam CT proves better for visualizing some causes of hearing loss at half the radiation dose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: